Bionano Genomics Inc represents a strong commitment to advancing genomics research and revolutionizing the field of DNA analysis. The company's corporate philosophy revolves around developing innovative and high-quality genomic technology solutions that enable scientists and researchers to gain a better understanding of the human genome and its impact on human health. By leveraging their proprietary Saphyr system, Bionano Genomics Inc aims to provide accurate and comprehensive structural variation detection, offering valuable insights into genetic diseases and ultimately contributing to precision medicine. With a focus on collaboration, integrity, and continuous innovation, Bionano Genomics Inc strives to empower the scientific community in unraveling the complexities of the genome.

Bionano Genomics Inc is primarily present in the United States.

Bionano Genomics Inc has achieved significant milestones in its journey. One of the major accomplishments is the development of the Saphyr System, a revolutionary genomic platform that enables the detection of structural variations in DNA. This cutting-edge technology has paved the way for advancements in genomics research, allowing scientists and clinicians to gain a deeper understanding of genetic diseases and cancer. Furthermore, Bionano Genomics has successfully established collaborations with renowned research institutions and biotech companies, further validating its innovative solutions. With its continuous dedication to advancing genomics, Bionano Genomics Inc stands as a frontrunner in the field, driving breakthroughs in personalized medicine and genetic diagnostics.

Bionano Genomics Inc is a leading genomics company that specializes in revolutionary tools for structural variation analysis and genome mapping. Founded in 2003, the company has emerged as a key player in the genomics industry, catering to the needs of researchers and clinicians worldwide. Bionano Genomics Inc has developed the Saphyr system, a cutting-edge platform that offers high-resolution detection of structural variations in the human genome. Leveraging its expertise in optical genome mapping, Bionano Genomics Inc has made significant contributions to the study of genetic diseases, cancer research, and agrigenomics. With its innovative technologies, Bionano Genomics Inc is committed to advancing genomics research and revolutionizing the way genetic variations are detected and understood.

The main competitors of Bionano Genomics Inc in the market include companies such as Illumina Inc, Pacific Biosciences of California Inc, and Oxford Nanopore Technologies.

Bionano Genomics Inc is primarily active in the field of life sciences and biotechnology.

Bionano Genomics Inc operates under the business model of developing and commercializing innovative technologies for genome analysis. The company specializes in optical mapping, an approach that provides high-resolution analysis of genomic structural variation. Bionano Genomics Inc's platform, Saphyr system, enables researchers to detect and study variations in DNA in a more accurate and efficient manner. By offering a unique solution for genome analysis, Bionano Genomics Inc aims to improve disease research, diagnostic testing, and drug development processes.

مُعامل القيمة السوقية إلى الأرباح لـ Bionano Genomics هو ؜-٠٫٠٦.

مُعامِل القيمة إلى المبيعات Bionano Genomics هو ٠٫٢٣.

نقاط جودة AlleAktien لـ Bionano Genomics هي 3/10.

المتوقعة Bionano Genomics الإيرادات هي ٢٩٫٤٩ مليون. USD.

صافي الربح المتوقعة Bionano Genomics هو ؜-١١٧٫١١ مليون. USD.

Bionano Genomics Inc. is a company specialized in the development of devices for genomic research. The company offers both hardware and software solutions that allow researchers to collect fast and precise data on DNA sequencing. The business model of Bionano is based on three main sectors: genomic research in the areas of health, agriculture, and industrial biotechnology. The company provides a variety of solutions in each of these sectors to ensure that customers can achieve their specific research goals. Bionano offers innovative technology for genome analysis and sequencing, supports research in health, agriculture, and industrial biotechnology, and provides products like the Saphyr® system to assist researchers in working quickly and efficiently.

يوزع Bionano Genomics أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Bionano Genomics في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـBionano Genomics هو US09075F1075.

رمز WKN لـ Bionano Genomics هو A2JRLZ.

الرمز المُختصر لـ Bionano Genomics هو BNGO.

خلال آخر 12 شهراً، دفعت Bionano Genomics توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Bionano Genomics خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Bionano Genomics هي .

Bionano Genomics يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Bionano Genomics دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Bionano Genomics يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Bionano Genomics المُعلن عنها في ٢٤‏/١٢‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٤‏/١٢‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٤‏/١٢‏/٢٠٢٤.

في العام 2023، وزعت Bionano Genomics 0 USD كأرباح أسهم.

يتم توزيع أرباح Bionano Genomics بالعملة USD.